Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BBIO

BridgeBio Pharma Inc

Dec 26 • 04:00PM ET

28.39

Dollar change -0.14
Percentage change -0.49	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI IWM VB XBI VXF VBK IBB IWO SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.41	Insider Own	21.85%	Shs Outstand	188.99M	Perf Week	9.28%
Market Cap	5.37B	Forward P/E	-	EPS next Y	-3.59	Insider Trans	-12.14%	Shs Float	147.70M	Perf Month	4.41%
Income	-438.86M	PEG	-	EPS next Q	-1.13	Inst Own	75.80%	Short Float	11.59%	Perf Quarter	15.97%
Sales	217.76M	P/S	24.64	EPS this Y	34.96%	Inst Trans	-2.07%	Short Ratio	8.53	Perf Half Y	12.66%
Book/sh	-6.51	P/B	-	EPS next Y	-39.79%	ROA	-66.49%	Short Interest	17.12M	Perf Year	-32.39%
Cash/sh	2.15	P/C	13.22	EPS next 5Y	26.80%	ROE	-	52W Range	21.62 - 44.32	Perf YTD	-29.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.29%	ROI	-88.62%	52W High	-35.94%	Beta	1.06
Dividend TTM	-	Quick Ratio	3.19	Sales past 5Y	117.77%	Gross Margin	96.56%	52W Low	31.31%	ATR (14)	1.38
Dividend Ex-Date	-	Current Ratio	3.19	EPS Y/Y TTM	38.26%	Oper. Margin	-244.62%	RSI (14)	58.25	Volatility	4.12% 5.03%
Employees	550	Debt/Eq	-	Sales Y/Y TTM	2209.77%	Profit Margin	-201.53%	Recom	1.29	Target Price	49.79
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	20.69%	Payout	-	Rel Volume	0.51	Prev Close	28.53
Sales Surprise	63.07%	EPS Surprise	14.28%	Sales Q/Q	-33.22%	Earnings	Nov 12 BMO	Avg Volume	2.01M	Price	28.39
SMA20	2.88%	SMA50	9.57%	SMA200	6.70%	Trades		Volume	1,025,141	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	SVB Leerink	Outperform	$66 → $24
Dec-27-21	Reiterated	Mizuho	Buy	$86 → $25
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy	$75
May-21-21	Initiated	UBS	Buy	$80
Mar-22-21	Reiterated	Goldman	Buy	$83 → $91
Feb-22-21	Resumed	JP Morgan	Overweight	$78
Feb-09-21	Resumed	Goldman	Buy	$83
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$64 → $87

Show Previous Ratings

Dec-24-24 08:40AM	BridgeBio price target raised to $50 from $45 at Evercore ISI (TipRanks)
Dec-13-24 07:18AM	Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Dec-03-24 08:00AM	Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology (GlobeNewswire)
Nov-26-24 09:10AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
06:50AM	BridgeBio price target raised to $45 from $42 at BofA (TipRanks)
04:16PM	Loading…
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily) +16.10%
09:40AM	BridgeBio Soars After Drug Gets Nod in Rare Heart Condition (Bloomberg)
09:03AM	FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market (Benzinga)
04:38AM	FDA approves BridgeBios Attruby for ATTR-CM treatment (Pharmaceutical Technology)
Nov-22-24 07:11PM	Attruby (acoramidis), a Near Complete TTR Stabilizer ( 90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients (GlobeNewswire)
02:16PM	BridgeBio heart drug approved by FDA, setting up battle with Pfizer (BioPharma Dive)
Nov-21-24 05:43PM	Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 02:44PM	BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market (Benzinga)
Nov-18-24 11:15AM	Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months (GlobeNewswire) -5.78%
05:30AM	BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia (GlobeNewswire)
08:39PM	Loading…
Nov-12-24 08:39PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -5.74%
08:45AM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	BridgeBio Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-05-24 07:30AM	BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management (GlobeNewswire)
Oct-31-24 10:01AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-24-24 07:30AM	BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 (GlobeNewswire)
Oct-04-24 05:17AM	3 Top Stocks That Could Still Rocket Higher in 2024 (Motley Fool)
Oct-03-24 07:30AM	BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions (GlobeNewswire)
Oct-01-24 05:00AM	5 FDA decisions to watch in the fourth quarter (BioPharma Dive)
Sep-30-24 01:17PM	BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease (Benzinga)
12:09PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:30AM	BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) (GlobeNewswire)
Sep-27-24 06:00PM	BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events (GlobeNewswire)
Sep-17-24 07:30AM	BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA (GlobeNewswire)
01:01PM	Loading…
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-11-24 01:44PM	BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition (Benzinga) -6.67%
07:35AM	BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine (BioPharma Dive)
Sep-10-24 04:45PM	BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program (GlobeNewswire)
04:45PM	BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Sep-06-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-24 04:03PM	Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug (The Wall Street Journal) +13.12%
01:10PM	Why Is BridgeBio Pharma Stock Trading Higher On Friday? (Benzinga)
10:50AM	BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension (GlobeNewswire)
Aug-29-24 07:30AM	BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 (GlobeNewswire)
Aug-28-24 07:30AM	BridgeBio Pharma to Participate in September Investor Events (GlobeNewswire)
Aug-26-24 07:30AM	BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence (GlobeNewswire)
Aug-21-24 07:43AM	BridgeBio sends rare disease drugs to new company (BioPharma Dive)
Aug-19-24 07:30AM	BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia (GlobeNewswire)
Aug-08-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 08:40AM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:41AM	BridgeBio Pharma: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-23-24 07:30AM	BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer (GlobeNewswire)
Jul-05-24 04:31PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-27-24 02:21PM	BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy? (Insider Monkey) +6.96%
Jun-26-24 10:12PM	10 Best Healthcare Stocks to Buy Under $50 (Insider Monkey)
Jun-18-24 07:30AM	BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) (GlobeNewswire)
Jun-10-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-24 07:30AM	BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace)
Jun-04-24 04:19PM	BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug (Investor's Business Daily) -6.38%
10:15AM	BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results (Investor's Business Daily)
08:00AM	BridgeBio data show sustained benefit for achondroplasia drug (BioPharma Dive)
07:30AM	BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia (GlobeNewswire)
Jun-03-24 04:01PM	BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 (GlobeNewswire)
May-29-24 04:01PM	Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-24-24 07:30AM	BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting (GlobeNewswire)
May-15-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-24 07:30AM	BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 (GlobeNewswire)
May-13-24 07:30AM	BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population (GlobeNewswire)
May-03-24 06:22AM	BridgeBio Oncology Therapeutics launches with $200m funding (Pharmaceutical Technology)
May-02-24 10:55PM	BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:27AM	BridgeBio Pharma Shares Decline After Q1 Financial Results (MT Newswires)
07:40AM	BridgeBio Pharma: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
07:00AM	BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline (GlobeNewswire)
03:00AM	BridgeBio spinout launches with $200M for KRAS cancer drugs (BioPharma Dive)
May-01-24 08:10AM	Pfizers strong Vyndaqel sales draw attention to rare disease drugs patent life (BioPharma Dive) +5.50%
Apr-25-24 10:02AM	Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-10-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-07-24 01:15PM	BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Mar-27-24 09:25AM	TipRanks Perfect 10 List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal (TipRanks)
Mar-20-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-24 11:53PM	BridgeBio Pharma Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -8.51%
Mar-04-24 04:17PM	BridgeBio Pharma Announces Proposed Public Offering of Common Stock (GlobeNewswire) -9.19%
04:05PM	BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug (Investor's Business Daily)
03:00AM	Bayer pays $310M to buy into BridgeBio heart drug (BioPharma Dive)
02:30AM	BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe (Reuters)
02:30AM	BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? (Investor's Business Daily)
02:30AM	BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM (GlobeNewswire)
Feb-22-24 08:40AM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:53AM	BridgeBio Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:52AM	BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials (GuruFocus.com)
07:30AM	BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Feb-15-24 10:00AM	Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for (Zacks) +14.14%
06:54AM	Alnylam changes to heart drug trial spark doubts, sinking shares (BioPharma Dive)
Feb-07-24 07:34AM	BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan (GlobeNewswire)
07:22AM	BridgeBio sells partial rights to dwarfism drug for $100M (BioPharma Dive)
Feb-06-24 07:30AM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-24 07:30AM	BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (GlobeNewswire)
Feb-02-24 07:00AM	BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months (GlobeNewswire)
Jan-30-24 07:00AM	Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics (PR Newswire)
Jan-29-24 12:35PM	3 Groundbreaking Biotech Stocks to Invest in Now (InvestorPlace) +5.29%

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kumar Neil	Chief Executive Officer	Nov 19 '24	Sale	22.41	27,389	613,826	4,897,443	Nov 20 08:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Nov 19 '24	Sale	22.41	4,156	93,137	93,758	Nov 20 07:57 PM
BRIAN STEPHENSON	Officer	Nov 19 '24	Proposed Sale	22.35	4,156	92,887		Nov 19 04:28 PM
NEIL KUMAR	Director	Nov 19 '24	Proposed Sale	22.35	27,389	612,144		Nov 19 04:24 PM
KKR Genetic Disorder L.P.	10% Owner	Sep 13 '24	Sale	25.75	5,800,000	149,350,000	25,260,971	Sep 17 06:44 PM
KKR Genetic Disorder L.P.	Affiliate	Sep 13 '24	Proposed Sale	26.95	5,800,000	156,310,000		Sep 13 05:04 PM
Kumar Neil	Chief Executive Officer	Aug 19 '24	Sale	24.69	27,389	676,256	4,897,443	Aug 20 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Aug 19 '24	Sale	24.69	4,155	102,590	85,192	Aug 20 06:27 PM
BRIAN STEPHENSON	Officer	Aug 19 '24	Proposed Sale	24.40	4,155	101,382		Aug 19 04:29 PM
NEIL KUMAR	Director	Aug 19 '24	Proposed Sale	24.40	27,389	668,292		Aug 19 04:27 PM
Scott Randal W.	Director	Jun 04 '24	Sale	31.30	1,500	46,950	4,000	Jun 05 04:53 PM
Scott Randal W.	Director	Jun 03 '24	Sale	28.84	1,000	28,843	5,500	Jun 05 04:53 PM
Scott Randal W.	Director	Mar 01 '24	Sale	34.00	2,500	85,000	6,500	Mar 05 04:00 PM
Valantine Hannah	Director	Feb 15 '24	Option Exercise	8.45	2,915	24,632	4,679	Feb 20 04:03 PM
Valantine Hannah	Director	Feb 15 '24	Sale	37.75	2,915	110,041	1,764	Feb 20 04:03 PM
Valantine Hannah	Director	Jan 16 '24	Option Exercise	8.45	2,915	24,632	4,679	Jan 18 04:10 PM
Valantine Hannah	Director	Jan 16 '24	Sale	37.97	2,915	110,683	1,764	Jan 18 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BBIO

BridgeBio Pharma Inc

Upgrade your FINVIZ experience